Shawnt Issakhanian

Abstract 4756: In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer

R. Finn, D. Slamon, S. Hirawat, 2014 .

Abstract 4150: Anti-tumor activity of the PI3K/mTOR pathway inhibitors alpelisib (BYL719) and everolimus (RAD001) in xenograft models of acquired resistance to CDK-4/6 targeted therapy

D. Slamon, S. Scherer, S. Hurvitz, 2017 .

MKAD-21 Suppresses the Oncogenic Activity of the miR-21/PPP2R2A/ERK Molecular Network in Bladder Cancer

D. Iliopoulos, A. Pantuck, D. Slamon, 2018, Molecular Cancer Therapeutics.

Abstract P6-17-11: The small molecule inhibitor of HER2, tucatinib, has potent and highly selective activity in preclinical modes of HER2-driven cancer

S. Hurvitz, D. Slamon, Tong Luo, 2019, Poster Session Abstracts.